FindTrial
Sign In

A STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF A HERB IN ADULT MALE SUBJECTS EXHIBITING MALE PATTERN BALDNESS

A MULTI-CENTER, RANDOMIZED, PARALLEL, DOUBLE-BLINDED, DOUBLE-ARM, PLACEBO-CONTROLLED STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF HERB AGERATUM CONYZOIDES IN OIL FORMULATION IN ADULT INDIAN MALES SUBJECTS EXHIBITING ANDROGENIC ALOPECIA (MALE PATTERN BALDNESS).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/12/002198
Enrollment
80
Registered
2011-12-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: AGERATUM CONYZOIDES: 3 ML TWICE DAILY FOR UPTO 90 DAYS by topical application. Control Intervention1: Placebo: 3 ML TWICE DAILY FOR UPTO 90 DAYS by topical application.

Sponsors

Gencor Pacific Organics India Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male subjects between ages of 18 to 41 years (both years inclusive). 2. Subjects must be able to be classified under any of the scales of Norwood / Hamilton Scale for menâ??s hair loss. 3. Subjects who are not using any other hair growth products for the last 30 days. 4. Subjects should agree to not use any other hair growth products during the study. 5. Subjects should agree to not to alter their hair style or dye their hair during the study. 6. Subjects should be able to comply with the study procedures and Schedule. 7. Subjects should be able to understand study information provided and give informed consent, after being explained by the study team.

Exclusion criteria

Exclusion criteria: 1. Subjects suffering from mycotic infections. 2. Subjects who have taken radiotherapy to scalp for cancer treatment. 3. Subjects with a history of systemic malignancy. 4. Subjects with a history of cutaneous malignancy. 5. Subjects with Nevi / cutaneous lesion currently. 6. Subjects with an evidence of an immune-compromised state. 7. Subjects with poorly controlled diabetes. 8. Subjects with clinically significant medical complaints. 9. Subjects with known psychiatric disease. 10. Subjects with serious local infection (e.g. cellulites, abscess) within 90 days of the signing of the informed consent 11. Subjects with systemic infection (e.g., pneumonia, septicemia) within 90 days of the signing of the informed consent. 12. Subjects with known hypothyroidism. 13. Subjects with known hyperthyroidism. 14. Subjects with Cicatricial alopecia

Design outcomes

Primary

MeasureTime frame
The objectives of this study are to evaluate the clinical efficacy and safety of Ageratum conyzoidesâ??s Oil Formulation in adult Indian Males Subjects exhibiting Androgenic Alopecia (Male Pattern Baldness).Timepoint: 90 DAYS—

Secondary

MeasureTime frame
Safety parametersTimepoint: 90 days treatment period—

Countries

India

Contacts

Public ContactV T Jagannathan

Consortium Clinical Research Pvt. Ltd.

naga@consortiumcr.com9789777777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026